Experimental drug cocktail targets Tough-to-Treat kidney cancer
NCT ID NCT06962787
Summary
This study is testing whether a new drug called BL-B01D1 works better when combined with standard kidney cancer medications for patients whose cancer has spread. Researchers want to see if this combination helps shrink tumors and extends patients' lives while monitoring side effects. The trial will enroll 260 adults with advanced kidney cancer who meet specific health requirements.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
Contact
Conditions
Explore the condition pages connected to this study.